New Chemotherapeutic Approaches in the Treatment of Lyme Borreliosis a

  title={New Chemotherapeutic Approaches in the Treatment of Lyme Borreliosis a},
  author={Benjamin J. Luft and David J. Volkman and John J Halperin and Raymond J. Dattwyler},
  journal={Annals of the New York Academy of Sciences},
1. It was demonstrated that while B. burgdorferi may be sensitive to relatively small concentrations of penicillin and ceftriaxone, the organism is killed slowly. This implies that, as in syphilis, prolonged blood levels of these drugs may be necessary in order to ensure cure. In contrast, the activity of tetracycline is more rapid in its action but is more dependent on drug concentration achieved. Unfortunately, the MIC and MBC for some strains are at or above the peak level achieved under… 

Antibiotic Susceptibility of Borrelia burgdorferi In Vitro and In Vivo

Knowledge of the susceptibility pattern of Borrelia burgdorferi is a prerequisite for the selection of an appropriate antibiotic therapy in Lyme borreliosis.

A perspective on the treatment of Lyme borreliosis.

The clinical and experimental rationale for the antibiotic regimens that are currently used and the need for a more standardized approach to treatment trials are reviewed.

Review of Treatment Options for Lyme Borreliosis

The parenteral agent ceftriaxone is the drug of choice for severe acute and chronic infections, due to good penetration into CSF, convenient single daily dosage regimen and proven high efficacy in clinical trials involving a wide variety of disseminated infections.

Antibiotic treatment of Lyme borreliosis.

  • R. DattwylerB. Luft
  • Medicine, Biology
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  • 1989

Minocycline in Lyme disease.

  • K. Liegner
  • Medicine, Biology
    Journal of the American Academy of Dermatology
  • 1992

Critical Remarks on Antibiotic Therapy

Patients treated with antibiotics for late manifestations of Lyme borreliosis may experience persistence or recurrence of their signs and symptoms, and their IgG antibody titer against B. burgdorferi may decline more slowly, if at all, than in patients treated in the early phase of the disease.

Effectiveness of antimicrobial treatment against Borrelia burgdorferi infection in mice

Having the potential to determine the presence of the spirochete through culture and histologic lesions makes the B. burgdorferi-inoculated C3H mouse model a valuable adjunct in evaluating chemotherapeutic options for Lyme disease.

Cefotaxime versus penicillin in the late stage of lyme disease — prospective, randomized therapeutic study

Third generation cephalosporins are far more effective onBorrelia burgdorferi spirochetes than penicillin G, as can be deduced fromin vitro susceptibility data.

Ineffectiveness of Tigecycline against Persistent Borrelia burgdorferi

Results extended previous studies with ceftriaxone, indicating that antibiotic treatment is unable to clear persisting spirochetes, which remain viable and infectious, but are nondividing or slowly dividing.

In vitro activity of vancomycin against the spirochete Borrelia burgdorferi

The in vitro activity of vancomycin against a variety of strains of B. burgdorferi and one strain of Borrelia hermsii was determined by use of a microdilution MIC method, demonstrating another class of microorganisms susceptible in vitro to vancomYcin.



European Borrelia burgdorferi isolated from humans and ticks culture conditions and antibiotic susceptibility.

  • V. Preac‐MursicB. WilskeG. Schierz
  • Biology, Medicine
    Zentralblatt fur Bakteriologie, Mikrobiologie, und Hygiene. Series A, Medical microbiology, infectious diseases, virology, parasitology
  • 1986

In vitro and in vivo susceptibility of the Lyme disease spirochete, Borrelia burgdorferi, to four antimicrobial agents

The antimicrobial susceptibility of Borrelia burgdorferi isolated from human spinal fluid was determined in vitro and in vivo. A broth dilution technique was used to determine the MBCs of four

Susceptibility of the Lyme disease spirochete to seven antimicrobial agents.

The antimicrobial susceptibility of five Lyme disease spirochete strains (two human and three tick isolates) was determined and all strains were resistant to rifampin at the highest concentration tested.

Seronegative Lyme disease. Dissociation of specific T- and B-lymphocyte responses to Borrelia burgdorferi

It is concluded that the presence of chronic Lyme disease cannot be excluded by the absence of antibodies against B. burgdorferi and that a specific T-cell blastogenic response to the spirochete is evidence of infection in seronegative patients with clinical indications of Chronic Lyme disease.

Treatment of the early manifestations of Lyme disease.

For patients with early Lyme disease, tetracycline appears to be the most effective drug, then penicillin, and finally erythromycin; with all three antibiotic agents nearly half of the patients had minor late symptoms such as headache, musculoskeletal pain, and lethargy.

Successful parenteral penicillin therapy of established Lyme arthritis.

It is concluded that established Lyme arthritis can often be treated successfully with parenteral penicillin, however, neither of the regimens that are tested is uniformly effective, and further experience will be needed to determine the optimal course of therapy.

Neurologic abnormalities of Lyme disease: successful treatment with high-dose intravenous penicillin.

High-dose intravenous penicillin is effective therapy for neurologic abnormalities of Lyme disease and the duration of meningitic syndrome was significantly shorter in those givenPenicillin.

Isolation and cultivation of Lyme disease spirochetes.

  • A. Barbour
  • Biology, Medicine
    The Yale journal of biology and medicine
  • 1984
Observations on the growth of Lyme disease spirochetes under different in vitro conditions may yield important clues to both the metabolic characteristics of these newly discovered organisms and the pathogenesis of Lyme Disease.